Innovent Biologics, Inc. (1801.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 118.55B |
| Enterprise Value | 104.02B |
| P/E Ratio | 98.1 |
| PEG Ratio | 16.43 |
| Price/Sales Ratio | 7.77 |
| Price/Book Ratio | 5.78 |
| Enterprise/Revenue | 6.8 |
| Enterprise/EBITDA | 41.73 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
Profitability
| Profit Margin | 0.08 |
| Operating Margin | 0.12 |
AD
Management Effectiveness
| Return On Assets | 0.03 |
| Return On Equity | 0.06 |
Income Statement
| Revenue | 13.04B |
| Revenue/Share | 9.03 |
| Gross Profit | 10B |
| EBITDA | 1.33B |
| Net Income | 813.57M |
| Diluted EPS | 0.47 |
Balance Sheet
| Total Cash | 20B |
| Total Cash/Share | 11.59 |
| Total Debt | 2.32B |
| Total Debt/Equity | 0.11 |
| Current Ratio | 2.68 |
| Book Value Per Share | 12.49 |
Price History
| 52-Week Change | -4.23 |
| 52-Week High | 112.7 |
| 52-Week Low | 69.55 |
| Moving Average 50 Days | 97.53 |
| Moving Average 200 Days | 88.19 |
Statistics
| Average Volume | 11.74M |
| Shares Outstanding | 1.74B |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
